Adma Biologics reported $511.17M in Current Assets for its fiscal quarter ending in March of 2026.





Current Assets Change Date
Adma Biologics USD 511.17M 44.66M Mar/2026
Alnylam Pharmaceuticals USD 4.22B 168.65M Mar/2026
BioCryst Pharmaceuticals USD 373.62M 30.72M Mar/2026
Minerva Neurosciences USD 83.1M 70.08M Dec/2025
Novavax USD 850.82M 127.46M Mar/2026
Omeros USD 69.65M 26.53M Jun/2025
Takeda JPY 3.09T 25.94B Mar/2026